RxDoctor Payments Data

George Dy, MD

Internal Medicine · Mansfield, PANPI 1962415067

Payments from drug & device makers

$42,373in general payments, 2019–2025

Across 767 payments — averaging $55.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$20K
  • AstraZeneca$13K
  • Amgen$2K
  • Novo Nordisk$978
  • GSK$867
  • Lilly USA, LLC$859
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$4,24510%
  • Speaking & faculty fees$21,41051%
  • Travel & lodging$3,9759%
  • Food & beverage$12,52830%
  • Education$2151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,373 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,362
Medicare patients
150
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban300$242,430
FarxigaDapagliflozin Propanediol202$174,857
JardianceEmpagliflozin156$167,678
OzempicSemaglutide102$162,861
TradjentaLinagliptin184$132,675
ProliaDenosumab66$111,632
XareltoRivaroxaban78$105,026
KerendiaFinerenone104$102,914
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$100,294
TrulicityDulaglutide33$72,054
JanuviaSitagliptin Phosphate127$65,296
EntrestoSacubitril/Valsartan127$56,729
MounjaroTirzepatide39$56,432
Evenity (2 Syringes)Romosozumab-Aqqg22$54,989
GlyxambiEmpagliflozin/Linagliptin42$53,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Stiolto Respimat, Spiriva Respimat$503$421,514468 claims
PfizerEliquis$396$242,430300 claims
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere$12,690$202,429240 claims
AmgenProlia, Evenity (2 Syringes)$1,706$166,62188 claims
Novo NordiskOzempic$978$162,861102 claims
Johnson & JohnsonXarelto, Invokana, Procrit$19,986$154,289124 claims
Lilly USA, LLCTrulicity, Mounjaro$859$128,48672 claims
GSKTrelegy Ellipta, Breo Ellipta$867$116,346158 claims
BayerKerendia$477$102,914104 claims
MerckJanuvia$437$65,296127 claims
AbbVieLinzess, Creon$310$62,48974 claims
NovartisEntresto$288$56,729127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Mansfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →